

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/600,361
		<b>Filing Date</b>	June 20, 2003
		<b>First Named Inventor</b>	Jean-Marie Andrieu et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Emily M. Le
<b>Sheet</b>	1	of	6
		<b>Attorney Docket Number</b>	1187-R-02

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ANDRIEU, J.-M. et al., "Viro-immunopathogenesis of HIV Disease: Implications for Therapy," <u>Immunology Today</u> , 1995, vol. 16, no. 1, pages 5-7.	
		BAROUCH, D. H. et al., "Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes," <u>Nature</u> , January 17, 2002, vol. 415, pages 335-339.	
		BÖHLER, T. et al., "T-Cell Apoptosis in HIV-1-Infected Individuals Receiving Highly Active Antiretroviral Therapy," <u>Blood</u> , March 15, 2001, vol. 97, no. 6, pages 1898-1901.	
		CAVERT, W. et al., "Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection," <u>Science</u> , May 9, 1997, vol. 276, pages 960-964.	
		CHAMPAGNE, P. et al., "Skewed Maturation of Memory HIV-Specific CD8 T Lymphocytes," <u>Nature</u> , March 1, 2001, vol. 410, pages 106-111.	
		CHOUGNET, C. et al., "Normal Immune Function of Monocyte-Derived Dendritic Cells from HIV-Infected Individuals: Implications for Immunotherapy," <u>The Journal of Immunology</u> , 1999, vol. 163, pages 1666-1673.	
		CHUN, T.-W. et al., "Presence of an Inducible HIV-1 Latent Reservoir during Highly Active Antiretroviral Therapy," <u>Proc. Natl. Acad. Sci. USA</u> , November 1997, vol. 94, pages 13193-13197.	
		COHEN, O. J. et al., "Host Factors in the Pathogenesis of HIV Disease," <u>Immunological Reviews</u> , 1997, vol. 159, pages 31-48.	
		COLLIER, A. C. et al., "Treatment of Human Immunodeficiency Virus Infection with Zalcitabine, Zidovudine, and Zalcitabine," <u>The New England Journal of Medicine</u> , April 18, 1996, vol. 334, no. 16, pages 1011-1017.	
		DAVEY, R. T. Jr. et al., "HIV-1 and T Cell Dynamics after Interruption of Highly Active Antiretroviral Therapy (HAART) in Patients with a History of Sustained Viral Suppression," <u>PNAS</u> , December 21, 1999, vol. 96, no. 26, pages 15109-15114.	

Examiner Signature	Date
	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.08. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1456, Alexandria, VA 22313-1456.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/600,361
		<b>Filing Date</b>	June 20, 2003
		<b>First Named Inventor</b>	Jean-Marie Andrieu et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Emily M. Le
<b>Sheet</b>	2	<b>of</b>	6
		<b>Attorney Docket Number</b>	1167-R-02

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DONAGHY, H. et al., "Loss of Blood CD11c <sup>+</sup> Myeloid and CD11c <sup>+</sup> Plasmacytoid Dendritic Cells in Patients with HIV-1 Infection Correlates with HIV-1 RNA Virus Load," <u>Blood</u> , October 15, 2001, vol. 98, no. 8, pages 2574-2576.	
		FELDMAN, S. et al., "Decreased Interferon- $\alpha$ Production in HIV-Infected Patients Correlates with Numerical and Functional Deficiencies in Circulating Type 2 Dendritic Cell Precursors," <u>Clinical Immunology</u> , November 2001, vol. 101, no. 2, pages 201-210.	
		FENYÖ, E. M. et al., "Broad Cross-Neutralizing Activity in Serum is Associated with Slow Progression and Low Risk of Transmission in Primate Lentivirus Infections," <u>Immunology Letters</u> , 1996, vol. 51, pages 95-99.	
		FINZI, D. et al., "Latent Infection of CD4 <sup>+</sup> T Cells Provides a Mechanism for Lifelong Persistence of HIV-1, Even in Patients on Effective Combination Therapy," <u>Nature Medicine</u> , May 1999, vol. 5, no. 5, pages 512-517.	
		GRABAR, S. et al., "Clinical Outcome of Patients with HIV-1 Infection According to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy," <u>Annals of Internal Medicine</u> , September 19, 2000, vol. 133, no. 6, pages 401-410.	
		GRASSI, F. et al., "Depletion in Blood CD11c-Positive Dendritic Cells from HIV-Infected Patients," <u>AIDS</u> , 1999, vol. 13, no. 7, pages 759-766.	
		GRAY, C. M. et al., "Frequency of Class I HLA-Restricted Anti-HIV CD8 <sup>+</sup> T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)," <u>The Journal of Immunology</u> , 1999, vol. 162, pages 1780-1788.	
		HARRIGAN, P. R. et al., "Rate of HIV-1 RNA Rebound upon Stopping Antiretroviral Therapy," <u>AIDS</u> , 1999, vol. 13, no. 8, pages F59-F62.	
		HATANO, H. et al., "Pre-HAART HIV Burden Approximates Post-HAART Viral Levels Following Interruption of Therapy in Patients with Sustained Viral Suppression," <u>AIDS</u> , 2000, vol. 14, no. 10, pages 1357-1363.	
		HAYNES, B. F. et al., "Toward an Understanding of the Correlates of Protective Immunity to HIV Infection," <u>Science</u> , January 19, 1996, vol. 271, pages 324-328.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/600,361
		<b>Filing Date</b>	June 20, 2003
		<b>First Named Inventor</b>	Jean-Marie Andrieu et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Emily M. Le
<b>Sheet</b>	3	<b>of</b>	6
		<b>Attorney Docket Number</b>	1187-R-02

**NON PATENT LITERATURE DOCUMENTS**

Examiner initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HERMANS, J. F. et al., "CD8 <sup>+</sup> T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity," <u>The Journal of Immunology</u> , 2000, vol. 164, pages 3095-3101.	
		HIRSCH, V. M. et al., "Simian Immunodeficiency Virus Infection of Monkeys as a Model System for the Study of AIDS Pathogenesis, Treatment, and Prevention," <u>Advances in Pharmacology</u> , 2000, vol. 49, pages 437-477.	
		IBÁÑEZ, A. et al., "Quantification of Integrated and Total HIV-1 DNA after Long-Term Highly Active Antiretroviral Therapy in HIV-1-Infected Patients," <u>AIDS</u> , 1999, vol. 13, no. 9, pages 1045-1049.	
		JIN, X. et al., "An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes," <u>Molecular Medicine</u> , 2000, vol. 6, no. 9, pages 803-809.	
		KALAMS, S. A. et al., "Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy," <u>Journal of Virology</u> , August 1999, vol. 73, no. 8, pages 6721-6728.	
		KAUFMANN, D. et al., "CD4-Cell Count in HIV-1-Infected Individuals Remaining Viraemic with Highly Active Antiretroviral Therapy (HAART)," <u>The Lancet</u> , March 7, 1998, vol. 351, pages 723-724.	
		KNIGHT, S. C. et al., "Antigen-Presenting Cell Types," <u>Current Opinion Immunology</u> , 1993, vol. 5, pages 374-382.	
		KOSTENSE, S. et al., "Persistent Numbers of Tetramer+ CD8 <sup>+</sup> T Cells, but Loss of Interferon-gamma + HIV-Specific T Cells During Progression to AIDS," <u>Blood</u> , April 1, 2002, vol. 99, no. 7, pages 2505-2511.	
		LEDERGERBER, B. et al., "Clinical Progression and Virological Failure on Highly Active Antiretroviral Therapy in HIV-1 Patients: a Prospective Cohort Study," <u>The Lancet</u> , March 13, 1999, vol. 353, pages 863-868.	
		LEDERMAN, M. M. et al., "Immune Restoration with Antiretroviral Therapies: Implications for Clinical Management," <u>JAMA</u> , July 12, 2000, vol. 284, no. 2, pages 223-228.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1** Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Application Number</b>	10/600,361	
			<b>Filing Date</b>	June 20, 2003	
			<b>First Named Inventor</b>	Jean-Marie Andrieu et al.	
			<b>Art Unit</b>	1648	
			<b>Examiner Name</b>	Emily M. Le	
<b>Sheet</b>	4	of	6	<b>Attorney Docket Number</b>	1187-R-02

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LEVITZ, S. M., "Improvement in CD4+ Cell Counts Despite Persistently Detectable HIV Load," <u>The New England Journal of Medicine</u> , April 9, 1998, vol. 338, no. 15, pages 1074-1075.	
		LU, W. et al., "Prospective Views of HIV Pathology. Clues for Therapeutic Strategies," <u>Cell Activation Apoptosis in HIV Infection</u> , Plenum Press, NY, 1995, pages 235-242.	
		LU, W. et al., "Enhanced Dendritic Cells-Driven Proliferation and Anti-HIV Activity of CD8 <sup>+</sup> T Cells by a New Phenothiazine Derivative, Aminoperazine," <u>The Journal of Immunology</u> , 2001, vol. 167, pages 2929-2935.	
		LU, W. et al., T-Cell Recovery in HIV-Infected Patients Experiencing Virologic Failure under Highly Active Antiretroviral Therapy, <u>Blood</u> , 2001b, vol. 97, pages 1900-1901.	
		LU, W. et al., "Multi-Target PCR Analysis by Capillary Electrophoresis and Laser-Induced Fluorescence," <u>Nature</u> , March 17, 1994, vol. 368, pages 289-271.	
		LU, W. et al., "Equivalent Amplification of Intrinsically Variable Nucleic Acid Sequences by Multiple-Primer-Induced Overlapping Amplification Assay. Applications for Universal Detection and Quantitation," <u>Nature Medicine</u> , September 1999, vol. 5, no. 9, pages 1081-1085.	
		LUDEWIG, B. et al., "Protective Antiviral Cytotoxic T Cell Memory Is Most Efficiently Maintained by Restimulation via Dendritic Cells," <u>The Journal of Immunology</u> , 1999, vol. 163, pages 1839-1844.	
		MOLLROY, D. et al., "Low CD83, but Normal MHC Class II and Costimulatory Molecule Expression, on Spleen Dendritic Cells from HIV <sup>+</sup> Patients," <u>AIDS Research and Human Retroviruses</u> , 1998, vol. 14, no. 6, pages 505-513.	
		McMICHAEL, A. J. et al., "Escape of Human Immunodeficiency Virus from Immune Control," <u>Annu. Rev. Immunology</u> , 1997, vol. 15, pages 271-296.	
		MEHLHOP, E. et al., "Enhanced In Vitro Stimulation of Rhesus Macaque Dendritic Cells for Activation of SIV-Specific T Cell Responses," <u>Journal of Immunology Methods</u> , 2002, vol. 260, pages 219-234.	
		NAIR, S. K. et al., "Induction of Primary Carcinoembryonic Antigen (CEA)-Specific Cytotoxic T Lymphocytes In Vitro Using Human Dendritic Cells Transfected with RNA," <u>Nature Biotechnology</u> , April 1998, vol. 16, pages 364-369.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicants unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/600,361
		<b>Filing Date</b>	June 20, 2003
		<b>First Named Inventor</b>	Jean-Marie Andrieu et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Emily M. Le
<b>Sheet</b>	5	of	6
		<b>Attorney Docket Number</b>	1187-R-02

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		NORBURY, C. C. et al., "Visualizing Priming of Virus-Specific CD8 <sup>+</sup> T Cells by Infected Dendritic Cells <i>In Vivo</i> ," <u>Nature Immunology</u> , March 2002, vol. 3, no. 2, pages 265-271.	
		PACANOWSKI, J. et al., "Reduced Blood CD123 <sup>+</sup> (Lymphoid) and CD11c <sup>+</sup> (Myeloid) Dendritic Cell Numbers in Primary HIV-1 Infection," <u>Blood</u> , November 15, 2001, vol. 98, no. 10, pages 3016-3021.	
		ROSSIO, J. L. et al., "Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins," <u>Journal of Virology</u> , October 1998, vol. 72, no. 10, pages 7992-8001.	
		SALERNO-GONÇALVES, R. et al., "Quantitative Analysis of the Antiviral Activity of CD8 <sup>+</sup> T Cells from Human Immunodeficiency Virus-Positive Asymptomatic Patients with Different Rates of CD4 <sup>+</sup> T-Cell Decrease," <u>Journal of Virology</u> , July 2000, vol. 74, no. 14, pages 6648-6651.	
		SALERNO-GONÇALVES, R. et al., "Lysis of CD4 <sup>+</sup> T Cells Expressing HIV-1 Gag Peptides by Gag-Specific CD8 <sup>+</sup> Cytotoxic T Cells," <u>Immunology Letters</u> , 1998, vol. 64, pages 71-77.	
		SANTINI, S. M. et al., "Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity <i>In Vitro</i> and in Hu-PBL-SCID Mice," <u>J. Exp. Med.</u> , May 15, 2000, vol. 191, no. 10, pages 1777-1788.	
		SAPP, M. et al., "Dendritic Cells Generated from Blood Monocytes of HIV-1 Patients Are Not Infected and Act as Competent Antigen Presenting Cells Eliciting Potent T-Cell Responses," <u>Immunology Letters</u> , 1999, vol. 66, pages 121-128.	
		SLOAND, E. M., et al., "Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4 <sup>+</sup> T Cells and Decreases Their Susceptibility to Apoptosis <i>In Vitro</i> and <i>In Vivo</i> ," <u>Blood</u> , August 1, 1999, vol. 94, no. 3, pages 1021-1027.	
		STRAUCHEN, J. et al., "Criteria for the Diagnosis of Acute Megakaryocytic Leukemia," <u>Blood</u> , 2001, vol. 97, pages 1898-1901.	
		WILSON, C. C. et al., "HIV-1-Specific CTL Responses Primed <i>In Vitro</i> by Blood-Derived Dendritic Cells and Th1-Biasing Cytokines," <u>The Journal of Immunology</u> , 1999, vol. 162, pages 3070-3078.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is submitted to the public in full, complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitution for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Complete if Known <b>Application Number</b> 10/600,361 <b>Filing Date</b> June 20, 2003 <b>First Named Inventor</b> Jean-Marie Andrieu et al. <b>Art Unit</b> 1648 <b>Examiner Name</b> Emily M. Le <b>Attorney Docket Number</b> 1187-R-02	
Sheet	6	of	6		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Applicant's unique disclosure designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual applicant. If you are unable to complete this form, please contact the nearest USPTO office for assistance or suggestions for reducing this time burden. Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. IF YOU HAVE QUESTIONS, PLEASE SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EAST42522495.1